Loading clinical trials...
Loading clinical trials...
An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer
Conditions
Interventions
Zanidatamab
Cisplatin
+3 more
Locations
184
United States
City of Hope(City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California, United States
Rocky Mountain Cancer Centers, LLP
Lone Tree, Colorado, United States
AdventHealth Hematology and Oncology
Orlando, Florida, United States
Winship Cancer Institute
Atlanta, Georgia, United States
The University of Kansas Cancer Center - Westwood
Westwood, Kansas, United States
Norton Cancer Institute - Audubon
Louisville, Kentucky, United States
Start Date
July 19, 2024
Primary Completion Date
December 1, 2028
Completion Date
April 1, 2030
Last Updated
March 24, 2026
NCT05489211
NCT07151118
NCT04900818
NCT07146646
NCT07398339
NCT06428409
Lead Sponsor
Jazz Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions